Steglatro

Discussion in 'Merck' started by anonymous, Aug 19, 2018 at 4:07 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Lets take a hot knife to this bull shit.
    Nationally this drug is <1%, its a bust.
    Belsomara is a dumpster fire

    Truth is 2021 or earlier CC will no longer exist. If u get caught in a mess there its your own fault for being a naive fucking moron. If your older and looking for a ticket to retire, this will be it.
     

  2. anonymous

    anonymous Guest

    Thank you for cutting to the chase. There are a lot of self centered, delusional people that need to be booted. I hope it happens sooner than later.
     
  3. anonymous

    anonymous Guest

    It is not self centered to report that Jardiance’s meeting centered on how well Steglatro is performing. Check out Gator chomp chomp, Steglatro is a rising star.
     
  4. anonymous

    anonymous Guest

    Yes, It is true. Boehringer did call a one day meeting of their salesforces across the country to discuss the major increase in Steglatro sales. They are very concerned about the long term impact of Steglatro sales growing so well on Jardiance sales. The strategy is obviously working with Steglatro. Last Gator sales report as the last pollster said showed major sales growth. Keep up the great work with Steglatro. Management is happy with how this drug is performing.
     
  5. anonymous

    anonymous Guest

    Hahahahaha!
     
  6. anonymous

    anonymous Guest

    Steglatro is fast becoming the nRX leader in the SGLT2 market. Look at the latest Gator numbers. Enjoy
     
  7. anonymous

    anonymous Guest

    Agree, Steglatro now has brought Farxiga to its knees. AZ is holding similar meetings like Boehringer did with Jardiance because Steglatro has grown tremendously this year. Both are concerned Steglatro is becoming the leader in the class
     
  8. anonymous

    anonymous Guest

    Steglatro has become the leading drug in the SGLT2 class. What a turnaround story. Stated a little slow but look at where it is in sales now. Jardiance and Farxiga have no plan on how to stop it. It is fast becoming the next Januvia
     
  9. anonymous

    anonymous Guest

    Steglatro has the other SGLT2s shaking in their boots. What a drug!
     
  10. anonymous

    anonymous Guest

    Steglatro’s latest numbers are astounding. Just overtook Farxiga as the number 2 in the SGLT2 class. Merck’s strategy is paying dividends. This has been an amazing ride watching Steglatro reach such prominence. As the last pollster said BI and AZ as well as Janssen just do not have an answer for Steglatro. The momentum has grown and is still growing. Check out where the company’s market share is!
     
  11. anonymous

    anonymous Guest


    Please don't be so honest and truthful next time. The truth hurts.
     
  12. anonymous

    anonymous Guest

     
  13. anonymous

    anonymous Guest

    I just looked at my latest data with Steglatro. I was astounded. Steglatro is growing and growing and growing. It is the fastest growing SGLT2. What a drug. We are going to make a lot of money with this drug.
     
  14. anonymous

    anonymous Guest

    Could not agree more. Steglatro seems to be reaching new highs each week. You just can’t wait to get new data each week when a drug is doing so well. Steglatro is taking over the space and is the add on of choice after metformin. WOW Merck has the next blockbuster
     
  15. anonymous

    anonymous Guest

    This could be the biggest blockerbuster drug in history!
     
  16. anonymous

    anonymous Guest

    Let’s be totally honest. Merck has a grand plan for Steglatro and is it working. Shares have grown 8 times nationally this year already and each week brings new highs. What a drug we have!!
     
  17. anonymous

    anonymous Guest

    Take a look at this week’s Steglatro numbers. Has to a mistake. RX count tripled This is a great drug
     
  18. anonymous

    anonymous Guest

    Checked my numbers. No mistake. Steglatro is now the second highest drug written in SGLT2 class after Jardiance
     
  19. anonymous

    anonymous Guest

    Steglatro continues to set the standard for Merck across the country. What a drug!!
     
  20. anonymous

    anonymous Guest

    Steglatro’s growth in the SGLT2 market has led to a second round of meetings wit AZ,BI and J&J to try to come up with a strategy to slow Steglatro down. There simply is no answer to Steglatro. It will continue to grow and grow ad grow. It has a dose of growth hormone that is unstoppable.